Now, Gilead has set a new benchmark for unbridled greed with its outrageous price for Sovaldi—a price
that some pharmacy industry sources suggest represents a retail
markup of 279,000% over the cost of actually producing the drug.”
In his letter to state Medicaid directors, Weinstein wrote, “Gilead is charging a higher price for this drug even though the cost to produce it is small. According to industry reports, Gilead produces Sovaldi for approximately $1.